sPLA2 inhibitor 1

更新时间：2024-01-13 14:10:32

sPLA2 inhibitor 1结构式	常用名	sPLA2 inhibitor 1	英文名	sPLA2 inhibitor 1
	CAS号	393569-31-8	分子量	487.63
	密度	1.1±0.1 g/cm3	沸点	720.9±60.0 °C at 760 mmHg
	分子式	C₃₁H₃₇NO₄	熔点	N/A
	MSDS	美版	闪点	389.8±32.9 °C

sPLA2 inhibitor 1用途

sPLA2抑制剂1是一种D-酪氨酸衍生物,是一种口服有效的分泌型磷脂酶A2(sPLA2)抑制剂,对人非胰腺分泌型PLA2亚型IIa(HNPPLA2 IIa)的IC50为29 nM。sPLA2抑制剂1具有抗炎活性[1]。

中文名	sPLA2抑制剂
英文名	KH064
英文别名	更多

描述	sPLA2抑制剂1是一种D-酪氨酸衍生物,是一种口服有效的分泌型磷脂酶A2(sPLA2)抑制剂,对人非胰腺分泌型PLA2亚型IIa(HNPPLA2 IIa)的IC50为29 nM。sPLA2抑制剂1具有抗炎活性[1]。
相关类别	信号通路 >> 代谢酶/蛋白酶 >> 磷脂研究领域 >> 炎症/免疫
靶点	sPLA2:29 nM (IC50)
体内研究	sPLA2抑制剂1(化合物2b；口服；5 mg/kg/天；接种关节炎原后第10-13天)显示出对水肿的显著抑制。药物治疗的大鼠表现为轻度囊性水肿和少量巨噬细胞浸润红髓[1]。
参考文献	[1]. Karl A Hansford, et al. D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 2003 Mar 3;4(2-3):181-5.

密度	1.1±0.1 g/cm3
沸点	720.9±60.0 °C at 760 mmHg
分子式	C₃₁H₃₇NO₄
分子量	487.63
闪点	389.8±32.9 °C
精确质量	487.272247
LogP	6.16
蒸汽压	0.0±2.4 mmHg at 25°C
折射率	1.573
储存条件	2-8°C

个人防护装备	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
安全声明 (欧洲)	22-24/25
危险品运输编码	NONH for all modes of transport

Inhibitors of secretory phospholipase A2 group IIA.

Curr. Med. Chem. 12(25) , 3011-26, (2005)

Phospholipases A2 cleave membrane phospholipids to release arachidonic acid, the precursor to a large family of pro-inflammatory eicosanoids including prostaglandins and leukotrienes that have been pr...

Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats.

J. Immunol. 176(11) , 7000-7, (2006)

The development of fibrosis in the chronically hypertensive heart is associated with infiltration of inflammatory cells and cardiac hypertrophy. In this study, an inhibitor of the proinflammatory enzy...

Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.

J. Thorac. Cardiovasc. Surg. 144(6) , 1479-85, (2012)

There are currently no targeted therapies against lung tumors with oncogenic K-ras mutations that are found in 25% to -40% of lung cancers and are characterized by their resistance to epidermal growth...

KH064

Benzenepentanoic acid, γ-[(1-oxo-7-phenylheptyl)amino]-4-(phenylmethoxy)-, (γS)-

MFCD06411576

sPLA2 inhibitor

(4S)-5-[4-(Benzyloxy)phenyl]-4-[(7-phenylheptanoyl)amino]pentanoic acid

5-(4-Benzyloxyphenyl)-4S-(7-phenylheptanoylamino)pentanoic acid